The conventional biomarkers of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are usually not expressed in metaplastic breast cancer (i.e., they are “triple negative” breast cancers). This evidence concerns the gene ERBB2 and breast carcinoma.